Physician profile
John M Knox
NPI 1396749347
$1,231.79
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $239 · 2021: $231 · 2022: $11.83.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $246.34 | 2019-2021 | |
| Pfizer INC. | $224.08 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $181.21 | 2019-2021 | |
| Galderma Laboratories, L.P. | $118.26 | 2019-2021 | |
| Abbvie INC. | $107.81 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $98.22 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $73.80 | 2019-2020 | |
| Genzyme Corporation | $55.43 | 2020-2021 | |
| Leo Pharma INC. | $36.68 | 2021 | |
| Celgene Corporation | $22.47 | 2019 | |
| Amgen INC. | $21.40 | 2020 | |
| Dusa Pharmaceuticals, INC. | $18.35 | 2019 | |
| Mylan Pharmaceuticals INC. | $15.91 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.83 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Knox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.